Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
73,147,470
-
Shares change
-
+12,829,912
-
Total reported value, excl. options
-
$208,518,897
-
Value change
-
+$38,013,987
-
Put/Call ratio
-
80%
-
Number of buys
-
62
-
Number of sells
-
-35
-
Price
-
$2.85
Significant Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q2 2021
129 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common shares as of Q2 2021.
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 73,147,470 shares
of 250,425,788 outstanding shares and own 29.21% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (34,005,379 shares), BlackRock Inc. (8,539,529 shares), VANGUARD GROUP INC (6,398,815 shares), Defender Capital, LLC. (5,036,720 shares), GEODE CAPITAL MANAGEMENT, LLC (2,338,584 shares), JPMORGAN CHASE & CO (1,952,035 shares), STATE STREET CORP (1,868,046 shares), Prescott General Partners LLC (1,851,851 shares), TWO SIGMA ADVISERS, LP (1,824,566 shares), and NORTHERN TRUST CORP (1,628,749 shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.